Keryx Biopharmaceuticals (KERX) Tops Q4 EPS by 5c; CEO Comments on Outlook
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reports a Q4 loss of $0.08 per share vs. consensus for $0.13 loss. Revenues ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
